|LETTER TO EDITOR
|Year : 2018 | Volume
| Issue : 2 | Page : 163
Cost and effectiveness of dengue vaccine: A report from endemic area, Thailand
Beuy Joob1, Viroj Wiwanitkit2
1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Department of Tropical Medicine, Hainan Medical University, Haikou, China
|Date of Web Publication||25-Oct-2018|
Dr. Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Joob B, Wiwanitkit V. Cost and effectiveness of dengue vaccine: A report from endemic area, Thailand. J Med Soc 2018;32:163
Dengue is an important mosquito-borne infection. It is common in tropical countries. In Thailand, a tropical country in Indochina, the dengue is highly prevalent and causes high morbidity and mortality each year. To manage dengue, the early diagnosis and prompt fluid replacement therapy are needed. For prevention of dengue, the dengue vaccine has just been developed and it has already been available at tertiary hospital in Thailand. Here, the authors report on the cost and effectiveness of available dengue vaccine (Dengvaxia) in Thailand. The cost in this work is referred to the unit cost at tertiary hospital in USD and the effectiveness is referred to previous validation study in Thailand. The cost in Thailand is equal to 324.9 USD. Focusing on effectiveness, comparing to nonvaccination baseline, the 3.2 times more immunoprotection can be derived. It means that it requires about 100 USD per capita per 1 time increased immunoprotection against dengue for an individual. This rate is significant higher than the reported lost per capita due to dengue in Thailand (1.65 USD). Comparing to the required cost, the incidence of the dengue in Thailand has to be more than 1:60 that the vaccine will becomes cost-effective. That mentioned expected incidence is too high from the present actual situation in Thailand, where the incidence has never been more than 1:1000. Nevertheless, the vaccine is also proved not to be able to complete protect against the disease. This seems that the cost-effectiveness of the vaccine seems to be problem in Thailand for implementation of the universal vaccination to local population.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Corbel V, Nosten F, Thanispong K, Luxemburger C, Kongmee M, Chareonviriyaphap T, et al.
Challenges and prospects for dengue and malaria control in Thailand, Southeast Asia. Trends Parasitol 2013;29:623-33.
Wiwanitkit V. Dengue fever: Diagnosis and treatment. Expert Rev Anti Infect Ther 2010;8:841-5.
Vigne C, Dupuy M, Richetin A, Guy B, Jackson N, Bonaparte M, et al.
Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination. Hum Vaccin Immunother 2017;13:2004-16.
Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis 2013;7:e2055.
Bekoe C, Pansombut T, Riyapan P, Kakchapati S, Phon-On A. Modeling the geographic consequence and pattern of dengue fever transmission in Thailand. J Res Health Sci 2017;17:e00378.
Screaton G, Mongkolsapaya J. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine. Cold Spring Harb Perspect Biol 2018;10. pii: a029520.